In the latest trading session,, 16.5 million Anebulo Pharmaceuticals Inc (NASDAQ:ANEB) shares changed hands as the company’s beta touched -0.97. With the company’s most recent per share price at $3.17 changing hands around $1.34 or 73.50% at last look, the market valuation stands at $130.45M. ANEB’s last price was a premium, traded about 2.84% off its 52-week high of $3.08. The share price had its 52-week low at $0.80, which suggests the last value was 74.76% up since then. When we look at Anebulo Pharmaceuticals Inc’s average trading volume, we note the 10-day average is 15450.0 shares, with the 3-month average coming to 14.44K.
Analysts gave the Anebulo Pharmaceuticals Inc (ANEB) stock a consensus recommendation rating of Buy, calculated at a mean rating of 1.00. If we narrow down to specifics, the data shows that 0 out of 1 analysts rate the stock as a Sell, with a further 0 assigning it an Overweight rating. Of the remaining, 0 recommended ANEB as a Hold, 1 felt it is a Buy and 0 rated the stock as Underweight. Anebulo Pharmaceuticals Inc’s EPS for the current quarter is expected to be -0.05.
Anebulo Pharmaceuticals Inc (NASDAQ:ANEB) trade information
Instantly ANEB is in green as seen in intraday trades today. With action 98.44%, the performance over the past five days has been green. The company’s shares are showing year-to-date upside of 36.85%, with the 5-day performance at 98.44% in the green. However, in the 30-day time frame, Anebulo Pharmaceuticals Inc (NASDAQ:ANEB) is 108.88% up. Looking at the short shares, we see there were 36648.0 shares sold at short interest cover period of 5.16 days.
The consensus price target for the stock as assigned by Wall Street analysts is 6, meaning bulls need an upside of 47.17% from its recent market value. According to analyst projections, ANEB’s forecast low is 6 with 6 as the target high. To hit the forecast high, the stock’s price needs a -89.27% plunge from its current level, while the stock would need to soar -89.27% for it to hit the projected low.
The estimates for the next quarter sales put growth at 0.00%.
Looking at the company’s year-on-year earnings, data shows that the past 5-year has an earnings growth rate of -155.95%. The 2025 estimates are for Anebulo Pharmaceuticals Inc earnings to increase by 10.94%, but the outlook for the next 5-year period is at -12.86% per year.
ANEB Dividends
Anebulo Pharmaceuticals Inc is expected to release its next quarterly earnings report on 2025-May-13.
Anebulo Pharmaceuticals Inc (NASDAQ:ANEB)’s Major holders
If we look at who the major shareholders are, we find that insiders hold 40.54% of Anebulo Pharmaceuticals Inc shares while 55.05% of the shares are in the hands of institutional holders. The share float percentage for the stock currently stands at 92.58%. There are 55.05% institutions holding the Anebulo Pharmaceuticals Inc stock share, with 22NW, LP the top institutional holder. As of 2024-06-30, the company held 20.6927% of the shares, roughly 5.37 million ANEB shares worth $14.65 million.
LVW ADVISORS, LLC holds the second largest percentage of outstanding shares, with 2.4757% or 0.64 million shares worth $1.75 million as of 2024-06-30.
Among Mutual Funds, the top two as of Mar 31, 2025 were VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund and Fidelity Concord Street Trust-Fidelity Extended Market Index Fund . With 121.0 shares estimated at $0.38 million under it, the former controlled 0.29% of total outstanding shares. On the other hand, Fidelity Concord Street Trust-Fidelity Extended Market Index Fund held about 0.24% of the shares, roughly 96.72 shares worth around $0.31 million.
